326 results on '"Inanc, N."'
Search Results
2. AB0857 ASSOCIATIONS AMONG PATIENT EMPOWERMENT, PATIENT ENGAGEMENT, PATIENT ACTIVATION AND CLINICAL MANIFESTATIONS IN PRIMARY SJÖGREN’S SYNDROME
3. POS1247 CHARACTERIZATION OF 284 PATIENTS PRESENTING WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OF SJÖGREN DISEASE: RESULTS FROM THE SJÖGREN BIG DATA REGISTRY
4. POS1266 THE EFFECTS OF IMMUNOSUPRESSIVE THERAPY ON GLANDULAR INVOLVEMENT IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
5. POS1246 CHARACTERIZATION OF 785 PATIENTS WITH PULMONARY MANIFESTATIONS OF SJÖGREN DISEASE: RESULTS FROM THE BIG DATA SJÖGREN REGISTRY
6. The provisional OMERACT ultrasonography score for giant cell arteritis
7. Exposure to air pollution as an environmental determinant of how Sjögren's disease is expressed at diagnosis
8. Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjögren's syndrome
9. OP0219 INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO BDMARDS: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTRIES (THE “JAK-POT” STUDY)
10. AB0647 THE SIGNIFICANCE OF A COMPREHENSIVE EXAMINATION OF DRY EYE DISEASE IN PRIMARY SJÖGREN SYNDROME AND ITS RELATIONSHIP TO EXTRAOCULAR MANIFESTATIONS
11. Identification of patients receiving individualized parenteral nutrition
12. UNINTENTIONAL MONOTHERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB AND DRUG SURVIVAL RATE OF TOFACITINIB
13. AB0494 COMPARISON OF CUTANEOUS SILENT PERIOD PARAMETERS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME WITH THE HEALTHY POPULATION
14. AB0420 UNINTENTIONAL MONOTHERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB AND DRUG SURVIVAL RATE OF TOFACITINIB
15. OP0266 TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS AS AN OVERALL MEASURE OF TOLERANCE AND SAFETY OF JAK-INHIBITORS: AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-pot” STUDY).
16. AB0574 PREDICTOR FACTORS IN EMPOWERMENT OF PATIENTS WITH PRIMARY SJOGREN SYNDROME IN THE FRAME OF VALUE BASED HEALTH CARE
17. POS0790 18F-FLUORODEOXYGLUCOSE (FDG) PET-CT IMAGING OF SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME AND ITS CORRELATION WITH ULTRASONOGRAPHIC SCORES AND SALIVARY FLOW RATE COMPARED TO HEALTHY CONTROLS
18. EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries
19. Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection
20. DISEASE DURATION AND HLA-B27 POSITIVITY ALTER LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS
21. A NATIONAL, MULTICENTER, SECONDARY DATA USE STUDY EVALUATING EFFICACY AND RETENTION OF FIRST-LINE BIOLOGIC TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-LIFE SETTING FROM TURKBIO REGISTRY
22. HETEROGENEITY IN ADVERSE EVENT ASSESSMENT BETWEEN COUNTRIES PARTICIPATING IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS USING JANUS KINASE INHIBITORS (THE JAK-POT STUDY)
23. LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN AXIAL SPONDYLOARTHRITIS IS HIGHER: DATA FROM TURKBIO
24. TREATMENT SATISFACTION, EXPECTATIONS, PATIENT PREFERENCES, AND CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): TURKISH COHORT RESULTS OF THE SENSE STUDY
25. Nutritional status and mediterranean diet adherence of the children and adolescents with down syndrome and their siblings
26. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis
27. Comparative effectiveness of JAK-inhibitors, TNF-inhibitors, abatacept and IL-6 inhibitors in an international collaboration of registers of rheumatoid arthritis patients (the 'JAK-POT' study)
28. DO COMORBIDITIES DECREASE THE FIRST TNF-INHIBITOR RETENTION AND TREATMENT RESPONSE IN AXIAL SPONDYLOARTHRITIS PATIENTS? DATA FROM TURKBIO
29. ARE THERE ANY DIFFERENCES BETWEEN ADULT-ONSET RHEUMATOID ARTHRITIS PATIENTS AND LATE-ONSET RHEUMATOID ARTHRITIS PATIENTS IN TERMS OF USE OF BIOLOGICAL DRUGS AND DRUG RETENTION RATE? RESULTS FROM THE TURKBIO REGISTRY
30. Influence of the age at diagnosis in the disease expression of primary Sjogren's syndrome : Analysis of 12,753 patients from the Sjogren Big Data Consortium
31. Serious infections under treatment with TNF-α antagonists compared to traditional DMARDs in patients with rheumatoid arthritis
32. The investigation of sacroiliitis with different imaging techniques in spondyloarthropathies
33. POS0093 HETEROGENEITY IN ADVERSE EVENT ASSESSMENT BETWEEN COUNTRIES PARTICIPATING IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS USING JANUS KINASE INHIBITORS (THE JAK-POT STUDY)
34. AB0479 LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN AXIAL SPONDYLOARTHRITIS IS HIGHER: DATA FROM TURKBIO
35. AB0561 DISEASE DURATION AND HLA-B27 POSITIVITY ALTER LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS
36. POS1486-HPR DAILY ACTIVITY IMPAIRMENT IS MEDIATED BY BOTH ORAL DRYNESS AND ORAL HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
37. AB0895-HPR A MODERATED MEDIATION ANALYSIS FOR POOR ORAL HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH BEHÇET’S DISEASE
38. AB0888-HPR EULAR SJOGREN’S SYNDROME PATIENT REPORTED INDEX-FATIGUE SCORE AND HADS-DEPRESSION SCORE MEDIATE IDENTITY SCORE OF ILLNESS PERCEPTION QUESTIONNAIRE IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
39. AB0893-HPR TREATMENT SATISFACTION, EXPECTATIONS, PATIENT PREFERENCES, AND CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): TURKISH COHORT RESULTS OF THE SENSE STUDY
40. AB0229 A NATIONAL, MULTICENTER, SECONDARY DATA USE STUDY EVALUATING EFFICACY AND RETENTION OF FIRST-LINE BIOLOGIC TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-LIFE SETTING FROM TURKBIO REGISTRY
41. Lack of association between IL-6 gene polymorphisms and rheumatoid arthritis in Turkish population
42. OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)
43. THU0290 THE EARLIER IMMUNOSUPPRESIVE TREATMENT MAY PREVENT MAJOR ORGAN INVOLVEMENT IN BEHCET DISEASE
44. THU0378 DO COMORBIDITIES DECREASE THE FIRST TNF-INHIBITOR RETENTION AND TREATMENT RESPONSE IN AXIAL SPONDYLOARTHRITIS PATIENTS? DATA FROM TURKBIO
45. THU0114 CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES
46. SAT0128 ARE THERE ANY DIFFERENCES BETWEEN ADULT-ONSET RHEUMATOID ARTHRITIS PATIENTS AND LATE-ONSET RHEUMATOID ARTHRITIS PATIENTS IN TERMS OF USE OF BIOLOGICAL DRUGS AND DRUG RETENTION RATE? RESULTS FROM THE TURKBIO REGISTRY
47. AB0414 ESSPRI COMPONENTS AND SALIVARY FLOW RATE ARE RELATED TO DAILY ACTIVITY IMPAIRMENT IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
48. No association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey
49. INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO BDMARDS: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTRIES (THE "JAK-POT" STUDY).
50. A composite index for determining the impact of oral ulcer activity in Behcetʼs disease and recurrent aphthous stomatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.